OKYO Pharma (OKYO) News Today $3.08 -0.04 (-1.28%) As of 12:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OKYO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Wall Street Zen Upgrades OKYO Pharma (NASDAQ:OKYO) to HoldAugust 11 at 2:31 AM | americanbankingnews.comOKYO Pharma (NASDAQ:OKYO) Raised to "Hold" at Wall Street ZenAugust 10 at 2:38 AM | marketbeat.comDauntless Investment Group LLC Invests $2.53 Million in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO)July 29, 2025 | marketbeat.comOKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMIJuly 19, 2025 | proactiveinvestors.comOKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMIJuly 19, 2025 | proactiveinvestors.comOKYO Slides Despite Fresh R&D FundingJuly 17, 2025 | baystreet.caOKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal PainJuly 17, 2025 | finance.yahoo.comOKYO Pharma Secures $1.9 Million to Boost Urcosimod DevelopmentJuly 17, 2025 | tipranks.comOKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapyJuly 17, 2025 | proactiveinvestors.comOKYO reports top-line data from neuropathic corneal pain therapy trialJuly 17, 2025 | finance.yahoo.comOKYO Pharma shares surge following promising Phase 2 data for eye pain treatmentJuly 16, 2025 | msn.comPositive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track DesignationJuly 16, 2025 | tipranks.comOKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal PainJuly 16, 2025 | tipranks.comOKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal painJuly 16, 2025 | proactiveinvestors.comOKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal PainJuly 16, 2025 | globenewswire.comOKYO Pharma (NASDAQ:OKYO) Trading Up 1% - Here's WhyJuly 10, 2025 | marketbeat.comOKYO Pharma (NASDAQ:OKYO) Shares Down 13.7% - Should You Sell?June 18, 2025 | marketbeat.comOKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insidersJune 14, 2025 | uk.finance.yahoo.comOKYO Pharma poised for breakout as Phase 2 trial nears results: analystsJune 11, 2025 | proactiveinvestors.comGoldman Small Cap Research Issues New Research Update on OKYO Pharma Limited | OKYO Stock NewsJune 11, 2025 | gurufocus.comTokyo stocks edge down amid caution over U.S.-China trade tensionsJune 3, 2025 | msn.comOKYO Pharma (NASDAQ:OKYO) Stock Price Up 0.5% - Should You Buy?May 28, 2025 | marketbeat.comOKYO Pharma CEO to present drug research for debilitating eye pain at Boston summitMay 19, 2025 | proactiveinvestors.comOKYO Pharma CEO to Present at Boston Drug Discovery SummitMay 19, 2025 | tipranks.comOKYO Pharma to Present at the GPCRs-Targeted Drug Discovery SummitMay 19, 2025 | globenewswire.comOKYO moves toward FDA talks after eye drug trial – ICYMIMay 2, 2025 | proactiveinvestors.comOKYO moves toward FDA talks after eye drug trial – ICYMIMay 2, 2025 | proactiveinvestors.comOKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal painMay 1, 2025 | proactiveinvestors.comOKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal painApril 30, 2025 | proactiveinvestors.comOKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal PainApril 30, 2025 | tipranks.comOKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal PainApril 30, 2025 | globenewswire.comOKYO Pharma CEO discusses FDA Fast Track filing for urcosimod - ICYMIApril 5, 2025 | proactiveinvestors.comOKYO Pharma confirms stability of drug candidateApril 2, 2025 | uk.investing.comOKYO Pharma reports long-term shelf stability of corneal pain treatmentMarch 31, 2025 | proactiveinvestors.comOKYO Pharma Announces Positive Data in Long-Term Stability of UrcosimodMarch 31, 2025 | globenewswire.comOKYO Pharma Limited (NASDAQ:OKYO) Short Interest UpdateMarch 18, 2025 | marketbeat.comOKYO Pharma Files Application for Fast Track Designation for Urcosimod in Treatment of Neuropathic Corneal PainMarch 12, 2025 | nasdaq.comOKYO Pharma seeks FDA Fast Track for eye pain drugMarch 12, 2025 | uk.investing.comOKYO Pharma seeks FDA fast track for eye pain treatmentMarch 12, 2025 | uk.investing.comOKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatmentMarch 10, 2025 | proactiveinvestors.comOkyo Pharma files for FTD with FDA for urcosimodMarch 10, 2025 | markets.businessinsider.comOKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal PainMarch 10, 2025 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for OKYO Pharma Limited Sponsored ADR (OKYO)February 18, 2025 | markets.businessinsider.comBuy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market PotentialFebruary 14, 2025 | tipranks.comOKYO Pharma secures USAN designation ‘urcosimod' for lead assetFebruary 12, 2025 | proactiveinvestors.comOKYO Pharma’s Lead Asset OK-101 Receives USAN as UrcosimodFebruary 12, 2025 | tipranks.comYi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory ChallengesFebruary 10, 2025 | tipranks.comOKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believeJanuary 31, 2025 | proactiveinvestors.comOKYO Pharma insiders acquire sharesJanuary 31, 2025 | proactiveinvestors.comOKYO Pharma Executives Increase Shareholdings, Affirming Market ConfidenceJanuary 31, 2025 | tipranks.com Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address OKYO Media Mentions By Week OKYO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OKYO News Sentiment▼-0.340.47▲Average Medical News Sentiment OKYO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OKYO Articles This Week▼31▲OKYO Articles Average Week Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SIGA News UPXI News SVRA News ATYR News PRTC News FLGC News SNDL News CMPS News KOD News ERAS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OKYO) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisChris Rowe has made legendary calls—Tesla at $13, Nvidia at $40, Bitcoin under $1,000, Amazon at 12 cents. Now...True Market Insiders | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredSell these stocks now—what to buy insteadSell these stocks now—Here’s what to buy instead Wall Street legend Marc Chaikin says you must know these 3...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access